Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | TLR4 | O00206 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25328114 | 0.98 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL | |
| Trifluoroacetic Acid SCHEMBL3331266 | 0.92 | ALDH1A1 (0.56) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL25674801 | 0.90 | ALDH1A1 (0.58) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL26986433 | 0.89 | ALDH1A1 (0.67) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL10321293 | 0.88 | ALDH1A1 (0.59) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL2901586 | 0.88 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL10449418 | 0.88 | ALDH1A1 (0.59) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL240039 | 0.88 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL240038 | 0.88 | ALDH1A1 (0.63) | ALDH1A1GAATSHREPHX1CTSL | |
| SCHEMBL27345291 | 0.88 | ALDH1A1 (0.59) | ALDH1A1GAATSHREPHX1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-02-19 | — | — | US | disclosed |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4637748-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4567033-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-06-11 | — | — | EP | disclosed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119630656-A | Heterocyclic compounds for inducing cleavage of mutant KRAS proteins | 安斯泰来制药株式会社 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024261256-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A pan-KRAS DEGRADER | ASTELLAS PHARMA INC. (JP) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024137502-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024054954-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024029613-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-02-08 | — | — | WO | disclosed |
| EP-2144910-A2 | OXAZOLIDINONE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| WO-2009126535-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009038974-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008126034-A2 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008122614-A1 | 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| CN-1208416-A | Isooxacephem derivatives | HOFFMANN LA ROCHE (CH) | 1999-02-17 | — | — | CN | disclosed |
| EP-0085291-B1 | 2-OXO-1-(AMINOCARBONYLAMINOSULFONYLAMINOCARBONYL)AZETIDINES | E.R. Squibb & Sons, Inc. (US) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3283/4885GAA 3135/4885TSHR 3021/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | ALDH1A1 2341/4885GAA 979/4885TSHR 1437/4885 |
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | ALDH1A1 4200/4885GAA 3579/4885TSHR 2384/4885 |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | ALDH1A1 169/4885GAA 288/4885TSHR 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.